Clinical trials: Placebo - Control
Healthy
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated
The main objectives of this trial are to investigate (1) safety, tolerability, pharmacokinetics and pharmacodynamics following multiple rising doses of BI 1569912; (2) tolerability of BI 1569912 in an up-titrating dosing scheme.
- Trial name
- NCT04978506
- Testing
- BI 1569912
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients
This study involves research about an investigational medicine called Amlexanox. The reason for this study is to find out how Amlexanox can improve type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver…
- Conditions
- Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01975935
- Testing
- Amlexanox
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan
Meniere's Disease
Famvir for Treatment of Hearing in Unilateral Meniere's Disease
The specific aim of this study is to determine the efficacy of treatment with famciclovir in unilateral Meniere's Disease patients, specifically whether hearing can be improved.
- Trial name
- Famvir (NCT01526408)
- Testing
- Famciclovir
- Volunteers
- 11 people
- Sponsor
- House Research Institute
Parkinson Disease
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease
This study is a placebo-controlled, double-blind trial that will investigate the safety and tolerability of molecular hydrogen, a promising antioxidant agent, in patients with early-stage Parkinson's Disease.
- Trial name
- NCT03971617
- Testing
- Hydrogen
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stony Brook University
Sjogren's Syndrome
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome
Background: An autoimmune disease is one in which the immune system attacks a person's own body. Sjogren's syndrome (SS) is an autoimmune disease. It often involves multiple systems and organs of the body.
- Trial name
- NCT04496960
- Testing
- tofacitinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Acute Myeloid Leukemia
A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia
To compare disease-free survival in patients 60 years or older with acute myeloid leukemia (AML) who are randomly assigned to receive either OCV-501 monotherapy or placebo.
- Trial name
- NCT01961882
- Testing
- OCV-501
- Where
- 14 sites in Japan, South Korea and 1 more
- Volunteers
- 134 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Study Evaluating Vabicaserin in Subjects With Schizophrenia
The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.
- Trial name
- NCT00563706
- Testing
- vabicaserin, risperidone
- Where
- 33 sites in United States, Canada
- Volunteers
- 199 people
- Sponsor
- Pfizer
Thoracolumbar Scoliosis
A Trial Comparing Single Intra-op Dose of Methadone Versus Placebo in Patients Undergoing Spine Surgery
Scoliosis is a disease that involves lateral and/or rotational deformity of the spine and can affect up to 4% of the population.
- Trial name
- NCT02206685
- Testing
- Methadone, Normal Saline
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Huntington Disease
A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
- Trial name
- NCT05358717
- Testing
- PTC518
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Pain
"Lidocaine 4% Cream (LMX4) vs Placebo for Pain Due to Lumbar Puncture in Infants 0-60 Days of Age."
The study's hypothesis is LMX4 cream, a topical anesthetic cream, will reduce the pain of infants undergoing Lumbar Puncture (spinal tap).
- Trial name
- NCT00533468
- Testing
- Lidocaine Cream 4%
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- State University of New York at Buffalo
Non-small Cell Lung Cancer (NSCLC)
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with…
- Trial name
- SKYSCRAPER-06 (NCT04619797)
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- 127 sites in United States, Belgium and 19 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Acne Vulgaris
Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris
Actavis has developed a generic formulation of clindamycin 1.2% and benzoyl peroxide 3.75% gel. This study is designed to evaluate the safety and efficacy of this formulation in subjects with Acne Vulgaris
- Trial name
- NCT02616614
- Testing
- Onexton, Clindamycin/benzoyl peroxide gel
- Where
- 17 sites in United States
- Volunteers
- 862 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Psoriasis
A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis
This study is a phase I, randomised, double blind (sponsor unblinded), placebo-controlled, single ascending dose study GSK2831781 administered by IV.
- Trial name
- NCT02195349
- Testing
- GSK2831781
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This randomized phase II trial studies how well bevacizumab with or without everolimus works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT00886691
- Testing
- Bevacizumab, Everolimus, Laboratory Biomarker Analysis
- Where
- 45 sites in United States
- Volunteers
- 150 people
- Sponsor
- GOG Foundation
Alcoholic Hepatitis
Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
The main purpose of the study is to test if taking a study drug called emricasan (also known as IDN-6556 and PF-03491390) will affect overall patient survival after one month of treatment.
- Trial name
- AH (NCT01912404)
- Testing
- IDN-6556
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Colitis, Crohn's Disease
NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease
The objective of this NIH-specific substudy is immunologic monitoring of cytokine and immune cell responses in subjects undergoing treatment with AIN457 (human monoclonal anti-human interleukin-17A) for moderate to severe Crohn's…
- Conditions
- Colitis, Crohn's Disease, Inflammatory Bowel Disease
- Trial name
- NCT00936585
- Testing
- Immunologic Monitoring
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hypertension
Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
- Trial name
- NCT00362115
- Testing
- Azilsartan Medoxomil, Olmesartan
- Where
- 54 sites in United States, Argentina and 2 more
- Volunteers
- 449 people
- Sponsor
- Takeda
Agitation Associated With, Alzheimer's Disease
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
To compare the efficacy of 2 fixed doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder
- Trial name
- NCT01862640
- Testing
- Brexpiprazole, OPC-34712
- Where
- 85 sites in United States, Croatia and 5 more
- Volunteers
- 433 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Amyotrophic Lateral Sclerosis
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine whether Gilenya, also known as fingolimod, is safe and tolerable in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01786174
- Testing
- Gilenya
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Erectile Dysfunction
Treatment of Erectile Dysfunction II
Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-5 versus placebo for the treatment of…
- Trial name
- NCT01037218
- Testing
- Udenafil
- Where
- 40 sites in United States
- Volunteers
- 601 people
- Sponsor
- Warner Chilcott
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.